Hence, PARPs have become attractive targets in cancer therapeutics for the possibility of inducing the so-called synthetic lethality [145] in cells bearing HR defects, by inhibiting PARP activity and thus leading to cell death upon accumulation of unrepaired double strand breaks. Here, PARP1 is linked to cancer.